News

September 21 was World Alzheimer’s Day, a fitting occasion to announce that a recent study from Finnish and Swedish researchers has confirmed that MedUni Vienna scientists were right: Multimodal everyday training does, indeed, have a beneficial effect upon cognitive abilities such as planning and implementing projects. That is true for…

Cure Alzheimer’s Fund recently announced that it has awarded over $6 million in research grants this year to support scientific projects working to improve our knowledge of Alzheimer’s disease (AD) and to develop potential treatments. In total in 2016, so far, the organization has funded 29 projects in the U.S. and…

Twenty-five years have passed since researchers launched the idea that Alzheimer’s is a direct result of clumps of amyloid-beta littering the brain. The amyloid hypothesis of Alzheimer’s disease, as it is called, quickly raised hopes among researchers and patients alike that the dreaded disease would soon be under our control. But…

Researchers at the University of British Columbia (UBC) have found that many online resources about how to prevent Alzheimer’s disease (AD) are not accurate and can mislead readers. In a survey of online resources, UBC researchers found that a series of websites offered poor advice and one in five was…

The U.S. Food and Drug Administration (FDA) issued a draft guidance in 2013 to encourage research  in people at the earliest stages of Alzheimer’s disease, with no symptoms or no obvious symptoms. The update has had effect, with new clinical trials looking at Alzheimer’s patients without noticeable dementia, when they…

Researchers at the  the Salk Institute, in California, have shown, in a mouse study, that increasing the levels of a specific protein in the brain leads to improvement of memory deficits associated with Alzheimer’s disease. The new study, titled “Neuregulin 1 Improves Cognitive Deficits And Neuropathology In An Alzheimer’s…

Aducanumab, an amyloid-fighting medication being developed by Biogen for Alzheimer’s disease (AD), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The treatment is currently being evaluated in two large-scale Phase 3 trials, both of which are recruiting Alzheimer’s patients. The FDA’s fast track program allows for faster…

The National Institutes of Health’s recent $40 million award over the next five years will provide a new stage of research for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), an NIH public-private partnership. The ADNI is supported by the Foundation for the National Institutes of Health (FNIH), which anticipates $20…

An air pollutant found in industrial areas, magnetite, could be contributing to the development of neurological conditions such as Alzheimer’s disease (AD), according to new study out of the United Kingdom and Mexico. The study, “Magnetite pollution nanoparticles in the human brain,” was recently published in the journal Proceedings of the…

An investigational treatment for Alzheimer’s disease (AD) could be on the horizon, according to a study from researchers at Biogen and the University of Zurich. Aducanumab, a human monoclonal antibody, shows evidence of reducing Alzheimer’s amyloid plaques — the culprit behind AD-induced brain cell death. The treatment candidate is potentially…